Ameriprise Financial Inc Iveric Bio, Inc. Transaction History

Ameriprise Financial Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$26.24 - $39.63 $31.9 Million - $48.1 Million	-1,214,980 Reduced 97.73%	28,219 $1.11 Million
Q1 2023 May 15, 2023	BUY	$18.67 - $24.56 $2.8 Million - $3.68 Million	150,021 Added 13.72%	1,243,199 $30.2 Million
Q4 2022 Feb 14, 2023	BUY	$17.24 - $23.95 $14.7 Million - $20.4 Million	850,515 Added 350.49%	1,093,178 $23.4 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $2.28 Million - $4.51 Million	242,663 New	242,663 $4.35 Million
Q2 2022 Aug 15, 2022	SELL	$9.12 - $18.9 $9.49 Million - $19.7 Million	-1,041,082 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$12.15 - $16.83 $624,534 - $865,095	-51,402 Reduced 4.71%	1,041,082 $17.5 Million
Q4 2021 Feb 14, 2022	SELL	$13.83 - $18.78 $103,766 - $140,906	-7,503 Reduced 0.68%	1,092,484 $18.3 Million
Q3 2021 Nov 15, 2021	BUY	$7.07 - $17.5 $47,270 - $117,005	6,686 Added 0.61%	1,099,987 $17.9 Million
Q2 2021 Aug 16, 2021	BUY	$5.69 - $7.17 $133,402 - $168,100	23,445 Added 2.19%	1,093,301 $6.9 Million
Q1 2021 May 17, 2021	BUY	$5.08 - $6.89 $1.32 Million - $1.79 Million	259,830 Added 32.08%	1,069,856 $6.61 Million
Q4 2020 Feb 12, 2021	BUY	$5.65 - $7.66 $4.58 Million - $6.2 Million	810,026 New	810,026 $5.6 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.